68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity
Top Cited Papers
Open Access
- 17 August 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Imaging
- Vol. 16 (1), 22
- https://doi.org/10.1186/s40644-016-0084-2
Abstract
Pheochromocytomas (PCC) and paragangliomas (PGL) are neuroendocrine tumours arising from pluripotent neural crest stem cells and are associated with neurons of the autonomic nervous system. PCCs/PGLs are often hereditary and multifocal, and their biologic behaviour and metabolic activity vary making imaging of these tumours challenging. The imaging gold standard has been I-123 MIBG complemented by CT or MRI. PGLs being neuroendocrine tumours express somatostatin receptors enabling imaging with Ga-68 DOTA-coupled peptides such as DOTATATE. Imaging with F-18 FDG also provides additional information regarding metabolic activity and biologic aggressiveness of these tumours, or, in some situations, reflecting metabolic reprogramming of these tumours. We report our experience using both Ga-68 DOTATATE and F-18 FDG PET/CT imaging in patients with PGLs and PCCs. This was a retrospective review of 23 patients with proven PGL/PCC who underwent both DOTATATE and FDG PET/CT. Seven patients also had I-123 MIBG SPECT/CT and 1 patient had I-124 MIBG PET/CT. Lesional intensity and patterns of uptake were analysed. DOTATATE and FDG were positive at most sites of disease (96.2 % vs 91.4 %), although uptake intensity was significantly higher on DOTATATE with a median SUV of 21 compared to 12.5 for FDG (p < 0.001). SUVmax on F-18 FDG was significantly higher (p < 0.001) in clinically aggressive cases. I-123/I-124 MIBG detected fewer lesions (30.4 %). Overall, Ga-68 DOTATATE PET/CT detected similar number but has significantly greater lesion-to-background contrast compared to F-18 FDG PET/CT. Combined with high specificity, patient convenience and relatively low cost, DOTATATE PET/CT should be considered the ideal first line investigation for imaging PGL/PCC. Depending on DOTATATE findings and the clinical question, FDG and MIBG remain useful and, in selected cases, may provide more accurate staging, disease characterisation and guide treatment choices.Keywords
This publication has 41 references indexed in Scilit:
- Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by F-18-Fluorodeoxyglucose (F-18-FDG) Positron Emission TomographyJNCI Journal of the National Cancer Institute, 2012
- Modern Nuclear Imaging for Paragangliomas: Beyond SPECTJournal of Nuclear Medicine, 2012
- Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular ImagingFrontiers in Oncology, 2012
- 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine TumorsJournal of Nuclear Medicine, 2011
- Brown Adipose Tissue in Humans Is Activated by Elevated Plasma Catecholamines Levels and Is Inversely Related to Central ObesityPLOS ONE, 2011
- SDH-related pheochromocytoma and paragangliomaBest Practice & Research Clinical Endocrinology & Metabolism, 2010
- Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and ParagangliomaJournal of Clinical Endocrinology & Metabolism, 2009
- Usefulness of 123I-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter TrialJournal of Nuclear Medicine, 2009
- A novel approach for reduction of brown fat uptake on FDG PETThe British Journal of Radiology, 2009
- Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma SyndromesJournal of Clinical Endocrinology & Metabolism, 2006